16.11

13.53% -2.52

Pre-market: 16.70 0.59 +3.66%

Bioage Labs Inc (BIOA)

Overview News Price History Discussions Forecast

Bioage Labs Inc stock is traded at $16.11, with a volume of 853.94K. It is down -13.53% in the last 24 hours and down -25.28% over the past month. Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.

Previous Close:

$18.63

Open:

$18.49

24h Volume:

853.94K

Relative Volume:

1.23

Market Cap:

$672.63M

Revenue:

$5.92M

Net Income/Loss:

$-75.79M

P/E Ratio:

-7.6203

EPS:

-2.1141

Net Cash Flow:

$-59.15M

1W Performance:

-24.08%

1M Performance:

-25.28%

6M Performance:

+203.39%

1Y Performance:

+254.85%

1-Day Range:

$15.68

$18.71

1-Week Range:

$15.68

$21.09

52-Week Range:

$2.88

$24.00

Bioage Labs Inc Stock (BIOA) Company Profile

Name

Bioage Labs Inc

Sector

Healthcare (1113)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

510-806-1445

Address

5885 HOLLIS STREET, EMERYVILLE

Employee

Twitter

Next Earnings Date

2026-03-26

Latest SEC Filings

BIOA's Discussions on Twitter

Compare BIOA vs TAK, ZTS, HLN, TEVA, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BIOA Bioage Labs Inc	16.11	672.63M	5.92M	-75.79M	-59.15M	-2.1141
TAK Takeda Pharmaceutical Co Adr	18.04	56.99B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	115.93	48.94B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	9.70	43.30B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	29.14	33.94B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	531.82	23.31B	3.18B	1.33B	1.04B	27.90

Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-25-26	Initiated	Oppenheimer	Outperform
Feb-18-26	Upgrade	Jefferies	Hold → Buy
Jan-27-26	Initiated	Piper Sandler	Overweight
Dec-05-25	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Oct-22-25	Upgrade	Citigroup	Neutral → Buy
Feb-28-25	Initiated	William Blair	Mkt Perform
Dec-10-24	Downgrade	Morgan Stanley	Overweight → Underweight
Dec-09-24	Downgrade	Citigroup	Buy → Neutral
Dec-09-24	Downgrade	Jefferies	Buy → Hold
Oct-21-24	Initiated	Citigroup	Buy
Oct-21-24	Initiated	Jefferies	Buy
Oct-21-24	Initiated	Morgan Stanley	Overweight

View All

Bioage Labs Inc (BIOA)

Bioage Labs Inc Stock (BIOA) Company Profile

Compare BIOA vs TAK, ZTS, HLN, TEVA, UTHR

Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades

Bioage Labs Inc Stock (BIOA) Latest News

Price Action: Can BioAge Labs Inc. lead its sector in growth2026 Review & High Accuracy Trade Alerts - baoquankhu1.vn

Oppenheimer reiterates Outperform on BioAge Labs stock at $60 By Investing.com - Investing.com India

Jefferies reiterates Buy on BioAge Labs stock citing NLRP3 progress By Investing.com - Investing.com India

Chipmakers Recap: Can BioAge Labs Inc lead its sector in growth2026 WrapUp & Technical Confirmation Alerts - baoquankhu1.vn

Jefferies reiterates Buy on BioAge Labs stock citing NLRP3 progress - Investing.com

BioAge Labs (NASDAQ: BIOA) registers shelf for future equity and debt offers - Stock Titan

BioAge Labs Full-Year 2025 Net Loss Narrows - Moomoo

BioAge Labs (NASDAQ:BIOA) Stock Price Down 9.8%Here's Why - MarketBeat

BioAge Labs Provides Business Updates - Lifespan Research Institute

BioAge Labs Reports Positive 2025 Financial Results and Advances BGE-102 NLRP3 Inhibitor Toward Phase 2 Trials in Cardiovascular and Ophthalmology Indications - Minichart

BioAge Labs, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

BioAge Labs 2025-2026 Pipeline: Advancing BGE-102 NLRP3 Inhibitor for Cardiometabolic Disease and Ophthalmology Based on Aging Biology Insights - Minichart

BioAge Highlights BGE-102 Progress and Financial Strength - TipRanks

BIOAGE Labs Inc reports results for the quarter ended December 31Earnings Summary - TradingView

BioAge Labs (NASDAQ: BIOA) boosts R&D and outlines cash runway to 2029 - Stock Titan

Earnings Flash (BIOA) BioAge Labs Posts 2025 Collaboration Revenue $9M, vs. FactSet Est of $7.1M - marketscreener.com

Earnings Flash (BIOA) BioAge Labs Posts 2025 Net Loss $2.24 a Share, vs. FactSet Est of $1.89 Loss - marketscreener.com

BioAge Labs (NASDAQ: BIOA) widens 2025 loss but extends cash runway to 2029 - Stock Titan

BioAge says oral drug cut a heart-risk marker 86% in Phase 1 - Stock Titan

BioAge Labs, Inc.(NasdaqGS: BIOA) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com

Certain Warrant of BioAge Labs, Inc. are subject to a Lock-Up Agreement Ending on 23-MAR-2026. - marketscreener.com

Certain Common Stock of BioAge Labs, Inc. are subject to a Lock-Up Agreement Ending on 23-MAR-2026. - marketscreener.com

BioAge Labs, Inc.: Fundamental Analysis and Financial Ratings | Y7G | US09077V1008 - marketscreener.com

If You Invested $1,000 in BioAge Labs Inc. (BIOA) - Stock Titan

Jefferies upgrades BioAge Labs (BIOA) - MSN

BioAge Labs (NASDAQ:BIOA) Trading Down 5.9%What's Next? - MarketBeat

BioAge Makes a Comeback, Yet Technical Indicators Lean Bearish - Bitget

Can BioAge Labs Inc expand its profit marginsMarket Performance Summary & Pattern Based Trade Signal System - baoquankhu1.vn

BioAge Labs (NASDAQ:BIOA) Shares Up 8.8%Should You Buy? - MarketBeat

BIOAGE Labs Inc expected to post a loss of 74 cents a shareEarnings Preview - TradingView

BioAge Labs, Inc. (NASDAQ:BIOA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Quarterly Recap: Will BioAge Labs Inc outperform small cap indexesTrade Volume Summary & Daily Entry Point Alerts - baoquankhu1.vn

BioAge Labs (NASDAQ:BIOA) Given New $52.00 Price Target at Citigroup - MarketBeat

Aug Update: Will BioAge Labs Inc outperform small cap indexesEarnings Recap Report & Smart Swing Trading Techniques - baoquankhu1.vn

Bioage Labs Inc receives Investment Bank Analyst Rating Update By Investing.com - Investing.com

BioAge Labs (BIOA) price target increased by 24.14% to 12.24 - MSN

Market Trends: How does BioAge Labs Inc perform in inflationary periodsTrade Volume Report & Entry and Exit Point Strategies - baoquankhu1.vn

BioAge Investors Lose Last Bid At Obesity Drug-Linked Suit - Law360

BioAge Labs (NASDAQ: BIOA) CMO exercises options, sells 7,433 shares in 10b5-1 trade - Stock Titan

[Form 4] BioAge Labs, Inc. Insider Trading Activity - Stock Titan

BioAge Labs (NASDAQ:BIOA) Shares Gap DownHere's Why - MarketBeat

BIOA (NASDAQ: BIOA) insider files Form 144 showing multiple sales - Stock Titan

Risk Analysis: How does BioAge Labs Inc perform in inflationary periods2025 Performance Recap & Community Driven Trade Alerts - baoquankhu1.vn

Investment Recap: How do insiders feel about BioAge Labs Inc2025 Geopolitical Influence & Weekly High Return Stock Opportunities - baoquankhu1.vn

BIOA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

BioAge Labs, Inc. (NASDAQ:BIOA) Short Interest Update - MarketBeat

The Gross Law Firm Notifies Shareholders of BioAge Labs, Inc.(BI - GuruFocus

BioAge Labs Touts Oral NLRP3 Inhibitor BGE-102 Data, Eyes CV Study and Retinal Expansion - Yahoo Finance

Oppenheimer Begins Coverage on BioAge Labs (NASDAQ:BIOA) - MarketBeat

This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Oppenheimer Initiates Coverage of BioAge Labs (BIOA) with Outperform Recommendation - Nasdaq

Bioage Labs Inc Stock (BIOA) Financials Data

Revenue

Net Income

Cash Flow

EPS

Similar to BIOA